These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 15250677)
1. Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia. Knight GW; McLellan D Br J Biomed Sci; 2004; 61(2):103-11. PubMed ID: 15250677 [TBL] [Abstract][Full Text] [Related]
2. [Tyrosine kinase inhibitors for the treatment of CML]. Heim D Ther Umsch; 2006 Apr; 63(4):249-54. PubMed ID: 16689455 [TBL] [Abstract][Full Text] [Related]
11. Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Sawyers CL Cancer Cell; 2002 Feb; 1(1):13-5. PubMed ID: 12086882 [TBL] [Abstract][Full Text] [Related]
12. [Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy]. Toga W; Kondo M; Tokoro A Nihon Yakurigaku Zasshi; 2003 Feb; 121(2):119-28. PubMed ID: 12616857 [TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Druker BJ Expert Opin Pharmacother; 2003 Jun; 4(6):963-71. PubMed ID: 12783592 [TBL] [Abstract][Full Text] [Related]
14. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Manley PW; Cowan-Jacob SW; Mestan J Biochim Biophys Acta; 2005 Dec; 1754(1-2):3-13. PubMed ID: 16172030 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Nardi V; Azam M; Daley GQ Curr Opin Hematol; 2004 Jan; 11(1):35-43. PubMed ID: 14676625 [TBL] [Abstract][Full Text] [Related]
16. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy. Druker BJ Eur J Cancer; 2002 Sep; 38 Suppl 5():S70-6. PubMed ID: 12528776 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy. Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964 [TBL] [Abstract][Full Text] [Related]
19. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor]. Nakajima M; Toga W Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002 [TBL] [Abstract][Full Text] [Related]
20. [Molecular-target therapy of Ph-positive leukemia by imatinib (tyrosine kinase inhibitor)]. Tauchi T; Ohyashiki K Gan To Kagaku Ryoho; 2003 Aug; 30(8):1065-70. PubMed ID: 12938259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]